Medidata Rave Omics Collaboration Uncovers Insights for Rare Disease Research


Applied Clinical Trials

The Castleman Disease Collaborative Network (CDCN) discovered new patient subgroups, based on previously unknown proteomic signatures, with Medidata’s Rave Omics, a machine learning-based solution. These discoveries, presented at the 60th Annual Meeting of the American Society of Hematology, provide insights into treatment response and potential new drug targets, highlighting the value of precision medicine.

Read the full release here.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.